Evidence map›Paper›PMID 33801308›Full record

ArticleMolecules (Basel, Switzerland)2021

Synthesis of Moracin C and Its Derivatives with a 2-arylbenzofuran Motif and Evaluation of Their PCSK9 Inhibitory Effects in HepG2 Cells.

Jagadeesh Nagarajappa Masagalli, Melanayakanakatte Kuberappa BasavanaGowda, Hee-Sung Chae, Won Jun Choi

Open access · goldAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jagadeesh Nagarajappa MasagalliCollege of Pharmacy and Integrated Research Institute for Drug Development, Dongguk University, Seoul 04620, Korea.ORCID 0000-0002-4672-9185
Melanayakanakatte Kuberappa BasavanaGowdaCollege of Pharmacy and Integrated Research Institute for Drug Development, Dongguk University, Seoul 04620, Korea.
Hee-Sung ChaeCollege of Pharmacy and Integrated Research Institute for Drug Development, Dongguk University, Seoul 04620, Korea.
Won Jun ChoiCollege of Pharmacy and Integrated Research Institute for Drug Development, Dongguk University, Seoul 04620, Korea.ORCID 0000-0002-2342-0468
Dongguk University · KR

Funding

Dongguk University 2018National Research Foundation of Korea (NRF) NRF-2017R1D1A1B03036116
6 · The paper itself

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key factor in several cardiovascular diseases, as it is responsible for the elevation of circulating low-density lipoprotein cholesterol (LDL-C) levels in blood plasma by direct interaction with the LDL receptor. The development of orally available drugs to inhibit this PCSK9-LDLR interaction is a highly desirable objective. Here, we report the synthesis of naturally occurring moracin compounds and their derivatives with a 2-arylbenzofuran motif to inhibit

Indexed as

PCSK9 InhibitorsBenzofuransCell ProliferationEnzyme InhibitorsHep G2 CellsHumansProprotein Convertase 9StilbenesbenzofuranBenzofuransEnzyme Inhibitorsmoracin CPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9Stilbenescardiovascular diseasesHepG2 cell lineslow-density lipoprotein cholesterolmoracin compoundsproprotein convertase subtilisin/kexin type 9structure activity relationships

Identifiers

PMID33801308
PMCPMC7958322
OpenAlexW3135058617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.